title: The clinical potential of Deprenyl in neurologic and psychiatric disorders.
abstract: This article reviews the results of clinical studies with Deprenyl in various neurologic and psychiatric disorders except Parkinson's disease. Promising results could be observed both in narcolepsy in a dose of at least 20 mg/day in three different trials and in one study of Tourette's syndrome including attention hyperactivity disorders using an average dosis of 8.1 mg/ day. Controversial results were reported for Alzheimer's disease. On the one hand significant improvement of cognitive functions was found by various authors. On the other hand in a more recent study no effect on the progression of the disease could be observed. For depression a higher dosage of deprenyl between 30 to 60 mg/day appears to be necessary for effective treatment. No positive results were found in amyotrophic lateral sclerosis and in tardive dyskinesias.
authors.affiliation: Department of Neurology, St. Josef-Hospital, Bochum, Federal Republic of Germany.
authors.forename: W
authors.initials: W
authors.lastname: Kuhn
authors.forename: T
authors.initials: T
authors.lastname: Müller
mesh_terms: D000328:Adult; D000368:Aged; D000544:Alzheimer Disease / Q000188:drug therapy; D000690:Amyotrophic Lateral Sclerosis / Q000188:drug therapy; D000928:Antidepressive Agents / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000627:therapeutic use; D002648:Child; D002986:Clinical Trials as Topic; D018592:Cross-Over Studies; D003863:Depression / Q000188:drug therapy; D004311:Double-Blind Method; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy*; D008875:Middle Aged; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use; D009290:Narcolepsy / Q000188:drug therapy; D009422:Nervous System Diseases / Q000188:drug therapy*; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D018697:Nootropic Agents / Q000627:therapeutic use*; D010302:Parkinson Disease, Secondary / Q000188:drug therapy; D012559:Schizophrenia / Q000188:drug therapy; D012642:Selegiline / Q000627:therapeutic use*; D013494:Supranuclear Palsy, Progressive / Q000188:drug therapy; D005879:Tourette Syndrome / Q000188:drug therapy; D016896:Treatment Outcome
chemical_list: D000928:Antidepressive Agents; D014150:Antipsychotic Agents; D008996:Monoamine Oxidase Inhibitors; D018696:Neuroprotective Agents; D018697:Nootropic Agents; D012642:Selegiline